Table 1.
Patient characteristics at baseline
| Dacomitinib | |||
|---|---|---|---|
| 15 mg QD (n = 3) | 30 mg QD (n = 3) | 45 mg QD (n = 7) | |
| Age, years | |||
| Median (range) | 56.0 (55–70) | 66.0 (64–71) | 65.0 (36–69) |
| Male/female, n (%) | 2/1 (66.7/33.3) | 1/2 (33.3/66.7) | 2/5 (28.6/71.4) |
| ECOG PS, n (%) | |||
| 0 | 1 (33.3) | 1 (33.3) | 3 (42.9) |
| 1 | 2 (66.7) | 2 (66.7) | 4 (57.1) |
| Smoking classification, n (%) | |||
| Never | 1 (33.3) | 2 (66.7) | 4 (57.1) |
| Smoker | 0 | 1 (33.3) | 1 (14.3) |
| Ex-smoker | 2 (66.7) | 0 | 2 (28.6) |
| Malignancy, n (%) | |||
| Breast (stage IV) | – | 1 (33.3) | – |
| Colon (stage IV) | – | – | 2 (28.6) |
| Lunga | 3 (100) | 2 (66.7) | 4 (57.1) |
| Metastatic neoplasm (stage IV) | – | – | 1 (14.3) |
| EGFR mutation, n (%) | |||
| Positive | 1 (33.3) | 1 (33.3) | 1 (14.3) |
| Wild-type | 0 | 0 | 3 (42.9) |
| Not done | 2 (66.7) | 2 (66.7) | 3 (42.9) |
| KRAS mutation, n (%) | |||
| Positive | 0 | 0 | 2 (28.6) |
| Wild-type | 0 | 0 | 1 (14.3) |
| Not done | 3 (100) | 3 (100) | 4 (57.1) |
| Prior treatment, n (%) | |||
| Surgery | 0 | 1 (33.3) | 3 (42.9) |
| Radiotherapy | 2 (66.7) | 1 (33.3) | 1 (14.3) |
| Chemotherapy | 3 (100) | 3 (100) | 7 (100) |
ECOG PS Eastern Cooperative Oncology Group Performance Status; EGFR epidermal growth factor receptor
aStage IV NSCLC except for one patient in the 30 mg cohort with stage IIIB NSCLC and one patient in the 15 mg cohort with SCLC